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Identity 
Hugo: VRK1 
Other names: VRK-1; MGC117401; MGC138280; 
MGC142070;  
Vaccinia related kinase 1;  
Serine/threonine-protein kinase VRK1;  
Vaccinia-related kinase 1 
Location: 14q32.2 
Local order: Centromere---PAPOLA--VRK1--
BCL11B---Telomere. 
DNA/RNA 
Description 
13 exons in 84.22 kilobases. Transcription initiated 
from cetromere to telomere direction. 
Transcription 
Initiation codon located in exon 2. Normal message is  
1702 nucleotides. Some alternatively spliced RNA 
messages have been detected; but they are likely to 
represent splicing intermediates since there is no 
protein has been detected expressed from these 
alternative messages in humans. 
Pseudogene 
None. 
There are two closely related genes VRK2 and VRK3. 
SNP: 289 single nucleotide polymorphisms identified 
in human VRK1. 
ALLELE VARIANTS: CA Polymorphisms. Near the 
PAPOLA (Polyadenyl polymerase) with respect to 
VRK1 there is a polymorphic dinucleotide (CA) 
sequence that has high heterozygosity (0.81). Might be 
a useful marker in the genetic study of disorders 
localized at the 14q32 region, such as autosomal 
recessive congenital microphthalmia (CMIC). 
 
 
VRK1 gene structure based on data available in the Ensembl release 43. Upstream non-coding exons (green). Coding exons (yellow), 3' 
unstranslated sequence (red). The size of the exons in nucleotides is indicated below each exon. Exon number is indicated within the 
exon. 
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ABRS: ATP-binding region signature 
SRPKAS: Ser/Thr protein kinases active-site signature 
ELTS: Endosomal-lysosomal targeting sequence 
NLS: Nuclear localization signal 
 
Protein 
Note: Enzyme Number (IUBMB): 'EC 2.7.11.1'. 
Description 
Protein of 396 aminoacids. 46 kDa. Serine-threonine 
kinase domain (residues 26-300). Nuclear localization 
signal (in C-terminal region). Protein 
autophosphorylated in several residues. 
Expression 
VRK1 is widely expressed in proliferating cells, normal 
and tumoral. It is not present in quiescent or 
differentiated cells that do not divide in human 
biopsies. 
Localisation 
Subcellular localisation varies depending on cell type 
and growth conditions. Most commonly VRK1 is 
expressed and detected in the nucleus, excluding the 
nucleolus. However, in some cells it is in the cytosol, 
particularly associated with endoplasmic reticulum and 
Golgi. 
Occasionally it is observed in the nucleolus, but outside 
the nucleus. The regulation of the subcellular 
localization is unknown. 
Function 
Serine-threonine kinase activity. 
Phosphorylates p53 in Threonine-18 preventing its 
interaction with Hdm2 and activates p53-dependent 
transcription. Phosphorylates c-Jun and ATF2 
transcription factors. VRK1 also phosphorylates BAF1 
required for nuclear envelope assembly. 
In human cell lines siRNA specific for VRK1 results in 
defective cell proliferation. The level of VRK1 protein 
is regulated proteolytically by a p53-dependent-
transcription mechanism. This mechanism results in the 
induction of a targeting of VRK1 to enter the 
endosomal-lysosomal pathway. 
Homology 
The kinase domain is highly homologous to that in 
other ser-thr kinases. The C-terminal region has no 
homology to any known protein or domain. This C-
terminal region of VRK1 is different form that in 
human VRK2, or in the VRK-1 homolog of distant 
species such as Drosophila, C. elegans or Dario Rerio. 
This C-terminal divergence suggest the possibility of 
different protein interactions and thus of differential 
regulation. 
Mutations 
Note: All mutations reported in study by Greenman el 
al., 2007. 
Germinal 
Normal:  
Mutation in nucleotide 45 in the cDNA coding region; 
A to G that is silent (A15A). 
Mutation in nucleotide 705 in the cDNA coding region; 
C to T that is silent (G235G). 
Somatic 
Colorectal carcinoma: Heterozygous mutation in 
nucleotide 42 in the cDNA coding region; T to C (silent 
S14S). 
Implicated in 
T-cell acute lymphoblastic leukemia 
Cytogenetics 
Translocation t(5;14)(q35;q32). BCR (Breakpoint 
cluster region), detected as a DNAseI hypersensitive 
site between VRK1 and BCL11B in T-cell acute 
lymphoblastic leukemia with t(5,14)(q35;q32). 
Hybrid/Mutated Gene 
Disregulation of TLX3 and NKX2-5 homeobox genes, 
but not of VRK1. 
Abnormal Protein 
None. 
Oncogenesis 
In this translocation the breakpoint occurs in a DNAseI 
hypersensitive site located between VRK1 and 
BCL11B genes; but the structure, or expression, of 
VRK1 does not appear to be affected. In this 
translocation there is a dysregulation of TLX3 and 
NKX2-5 homeobox genes (both on chromosome 5). 
Head and neck squamous cell 
carcinoma 
Oncogenesis 
Overexpression of VRK1 protein that positively 
correlates with hdm2, cdk2, cdk4 and survivin. 
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Neuroblastomas 
Cytogenetics 
Loss of heterozygosis (31 %) in marker (D14S987) in 
14q32.2 which is located 5' with respect to the VRK1 
gene. 
Colorectal carcinoma 
Cytogenetics 
Loss of heterozygosis (40-60 %) depending on markers 
(D14S65; D14S250; D14S5267) in 14q32.2 which is 
located 3' to the VRK1 gene at less than 0.3 Mb. 
D14S65 is 0.15 Mb 3' with respect to VRK1. 
Nasopharyngeal carcinoma 
Cytogenetics 
Loss of heterozygosis in marker (D14S51) in 14q32.2 
which is located 0.15 Mb 3' to the VRK1 gene. 
Chronic myelogenous leukemia (Blastic 
crisis) 
Cytogenetics 
Loss of heterozygosis in marker (D14S65) in 14q32.2 
which is located 0.15 Mb 3' to the VRK1 gene. 
Breakpoints 
 
 
Localization of loss of heterozygosis (LOH) and translocation breakpoints reported in 14q32.2. The breakpoint cluster region has 
multiple DNAseI hypersensitive sites. 
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